Expert Rev Clin Pharmacol. 2009;2(6):661-672. Several semisynthetic glycopeptide antibiotics for example dalbavancin, telavancin and oritavancin, have been developed to serve as an alternative to ...
The short-lived success of teicoplanin as an alternative to vancomycin motivated pharmacologic investigators to develop different antibiotic approaches. The failure of glycopeptide antibiotics led ...
The antibiotics market generated sales of US ... Theravance/Astellas), a glycopeptide approved in 2009; retapamulin (Altabax; GlaxoSmithKline), a pleuromutilin approved in 2008; and tigecycline ...
To understand how the ancestor of today's glycopeptide antibiotics—such as vancomycin, ristomycin and teicoplanin—might have looked like, the researchers used a combination of bioinformatics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback